US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 0.950
- +0.020+2.17%
Trading Nov 29 11:27 ET
19.67MMarket Cap-1461P/E (TTM)
1.074High0.940Low202.28KVolume0.940Open0.930Pre Close200.20KTurnover1.28%Turnover RatioLossP/E (Static)20.71MShares2.33052wk High-11.59P/B14.97MFloat Cap0.51252wk Low--Dividend TTM15.76MShs Float8.180Historical High--Div YieldTTM14.41%Amplitude0.400Historical Low0.989Avg Price1Lot Size
NeuroSense Therapeutics Stock Forum
Sign in to post a comment
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
NeuroSense Therapeutics (NASDAQ: NRSN) has secured a Type C meeting with the FDA on November 6, 2024, to discuss the design of its Phase 3 clinical trial for PrimeC, a potential ALS treatment. The meeting will focus on finalizing trial design and reviewing NDA submission readiness.
PrimeC has demonstrated significant results in reducing disease progression markers. The co...
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
NeuroSense Therapeutics (NASDAQ: NRSN) has secured a Type C meeting with the FDA on November 6, 2024, to discuss the design of its Phase 3 clinical trial for PrimeC, a potential ALS treatment. The meeting will focus on finalizing trial design and reviewing NDA submission readiness.
PrimeC has demonstrated significant results in reducing disease progression markers. The co...
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
NeuroSense Therapeutics (Nasdaq: NRSN) has provided an update on its plans to file for early commercialization approval for PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. The company plans to submit its dossier in Q2 2025, with an expected regulatory decision by Q1 2026.
The submissi...
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
NeuroSense Therapeutics (Nasdaq: NRSN) has provided an update on its plans to file for early commercialization approval for PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. The company plans to submit its dossier in Q2 2025, with an expected regulatory decision by Q1 2026.
The submissi...
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
NeuroSense Therapeutics (NASDAQ: NRSN) has initiated the regulatory process for early commercialization approval of PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This decision follows positive Phase 2b trial results showing PrimeC reduces ALS disease progression by 36% (p=0.009) and improves survival rates by 4...
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
NeuroSense Therapeutics (NASDAQ: NRSN) has initiated the regulatory process for early commercialization approval of PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This decision follows positive Phase 2b trial results showing PrimeC reduces ALS disease progression by 36% (p=0.009) and improves survival rates by 4...
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
$NeuroSense Therapeutics (NRSN.US)$ Reuters· 3 mins ago
Neurosense Therapeutics Granted Key U.S. Patent for Novel Primec Formulation, Its Lead Asset for ALS and Alzheimer's
Neurosense Therapeutics Granted Key U.S. Patent for Novel Primec Formulation, Its Lead Asset for ALS and Alzheimer's
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS).
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, mile...
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, mile...
1
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company known for developing novel treatments for severe neurodegenerative diseases, has recently announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM). This study evaluated both the safety and efficac...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company known for developing novel treatments for severe neurodegenerative diseases, has recently announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM). This study evaluated both the safety and efficac...
$NeuroSense Therapeutics (NRSN.US)$ Good News !!!
$NeuroSense Therapeutics (NRSN.US)$ Reuters· 3 mins ago
Neurosense Therapeutics Announces Positive Biomarker Data From ALS Phase 2B Clinical Trial
Neurosense Therapeutics Announces Positive Biomarker Data From ALS Phase 2B Clinical Trial
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
MomentumHunter : if only some volume.